期刊文献+

组合人工肾与单独血液透析治疗尿毒症疗效的对比研究

Contrast Research of Therapeutic Effect on Urinaemia with Component Artifi-cial Kidney and Hematodialysis
暂未订购
导出
摘要 目的比较组合人工肾与普通血液透析对尿毒症的治疗效果。方法将28例长期维持血透的患者进入组合人工肾治疗(称治疗组),并与单独血透治疗24例(称对照组)疗效进行对比研究,观察临床症状改善,血尿素氮(blood urea nitrogen,,BUN)、肌酐(creatinine,Cr)、中分子量物质(middle molecular substance,MMS)清除及血常规变化。结果两种方法在清除Bun、Cr方面无明显差异(P>0.05),治疗组在MMS的清除及临床症状的改善方面好于对照组,组间比较有明显差异(P<0.05)。治疗后,组间血常规中白细胞(WBC)、血小板(PLT)计数、血红蛋白含量(Hb)无明显变化(P>0.05)。结论组合人工肾能更好地清除体内中分子物质,明显改善患者临床症状,对血液系统无明显影响。 Objective To observe the therapeutic effects on urinaemia with component artificial kidney(CAK) and hematodialysis(HD). Methods 28 patients with urinaemia who needed long-term hematodialysis were considered as control group-treated with CAK,another group(n=24) as interfered one-treated with HD alone.The amelioration of clinical symptom,clearance rates of urea nitrogen(BUN),creatinine(CR),Middle Molecular Substance(MMS), and variation of blood regular test were all observed. Results Compared with control group,there were no significant difference to the clearance rates of BUN and CR(P〉0.05),but the clearance rate of MMS was higher and the amelioration of clinical symptom was more superior(P〈0.05),and there were no obvious difference on variation of white blood cell,hemoglobin and platelet(P〉0.05).Conclusion Using CAK could clear up MMS and ameliorate clinical symptom better than using HD alone,with no influence on the function of hematological system.
出处 《中国血液流变学杂志》 CAS 2007年第1期88-89,115,共3页 Chinese Journal of Hemorheology
关键词 组合人工肾 血液透析 中分子物质 Component Artificial Kidney Hematodialysis,Medium Molecule Substance
  • 相关文献

参考文献4

二级参考文献17

  • 1[1]Sato T, Shoji H, Koga N. Endotoxin adsorption by polymyxin B immo bileized fiber column in patients with systemic inflammatory rssponse syndrome: The Japanese Experiense, Therapeutic Apheresis and Dialysis,2003,7(2) :252 - 258
  • 2[2]Shoji H. Extracorporeal endotoxin removal for the treatment of sepsis:Endotoxin adsorption cartridge(Toraymyxin). Therapeutic Apheresis and Dialysis, 2003,7(1):108 - 114
  • 3[3]Schmaldienst S, Banyai S, Stulnig TM, et al. Prospective randomised cross- over comparison of three LDL - apheresis system in stain pretreated patients with familial hypercholesterolaemia. Athernsclerosis,2000,151(2) :493 - 7
  • 4[4]Ritter M. M, Parhofer K.G. Extracorporal low - density lipoprotein by innunoadsorption. Therapeutic Apheresis and Dialysis, 2003, 7 ( 3 ):370 - 372
  • 5[5]Nakaji S, Haynshi N. Adsorption for myasthenia gravis treatment:Medisorba MG - 50. Therapeutic Apheresis and dialysis, 2003,7 ( 1 ):78 - 84
  • 6[6]Hirata N, Kuriyama T, Yamawaki N. Immusorba TR and PH. Therapeutic Apheresis and Dialysis, 2003,7( 1 ) :85 - 90
  • 7[7]Bambauer R,Schiel R, Latza R,et al. LDL apheresis in clinical practice: long - term treatment of severe hyperlipidemia. Ther Apher, 1997,1(1): 49-51
  • 8[8]Brunton C, Varghese Z, Moorhead F. Lipoheresis in the nephrotic syndrome. kidney Int,1999,56(Suppl 71) :s6- s8
  • 9[9]Yamamoto T,Yammashita T. Low - density lioprotein apheresis using the liposorber system: feature and clinical benefits. Ther Apher, 1998, 2(1) :25- 30
  • 10[10]Bosch T, Keller C. Clinical effect of direct adorption of lipoprotein apheresis: Beyond cholesterol reduction. Therapeutic Apheresis and Dialysis, 2003, 7(3) :341 - 344

共引文献60

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部